PDCD1 and non-small cell lung carcinoma: In the ICI‐chemotherapy combination group, studies employing anti‐PD‐L1 drugs were associated with a higher rate of grade 3–5 AEs compared with anti‐PD1 drugs in first line for NSCLC (p = 0.0302).